- Edit My Profile
- My Communities and Email List Preferences
- My Disclosures of Interest
- My Workspaces
- My Presentations & Exams
- My Volunteer Profile
- My CPNP Transcript Center
- My Opportunities
My CPNP provides quick access to the most important features on cpnp.org.
You will see your important notices, and you will have direct access to your exams and other action items.
Log in now to see your personalized page.
Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. am J Psychiatry 2008;165(6):721-30. doi:10.1176/appi.ajp.2007.05091676.
OBJECTIVE: Response to atomoxetine, a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral methylphenidate, a long-acting methylphenidate preparation, in patients with attention deficit hyperactivity disorder (ADHD). METHOD: In a large placebo-controlled, double-blind study, patients ages 6-16 with ADHD, any subtype, were randomly assigned to receive 0.8-1.8 mg/kg per day of atomoxetine (N=222), 18-54 mg/day of osmotically released methylphenidate (...
Murray DW, Arnold LE, Swanson J, et al. A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). curr Psychiatry Rep 2008;10(5):424-31.
Over the past decade, the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder has provided a bewildering wealth of data (more than 70 peer-reviewed articles) addressing treatment-related questions for children with attention-deficit/hyperactivity disorder. However, the take-home messages for clinicians may not always be clear. Therefore, this article reviews key findings, including relative benefits of medication and behavioral treatments, long-term effects at 2 and 3 years...
If you have any questions, please contact us.